A centralised electronic Multidrug-Resistant Tuberculosis Advisory Service: the first 2 years

被引:12
作者
Jordan, T. S. [2 ]
Cullen, D. [1 ]
Davies, P. D. O. [1 ]
机构
[1] Liverpool Heart & Chest Hosp, Multidrug Resistant TB Advisory Serv, Liverpool L14 3PE, Merseyside, England
[2] Univ Hosp N Staffordshire, Dept Resp Med, Stoke On Trent, Staffs, England
关键词
tuberculosis; multidrug resistance; electronic; website;
D O I
10.5588/ijtld.11.0411
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least both rifampicin and isoniazid) has become a serious problem in the United Kingdom. As it is uncommon, no one clinician has sufficient experience of it to be confident in providing the best management for the patient. The model of a centralised system of management, such as is used in the Baltic countries, would seem a suitable method to adapt to the United Kingdom. With the agreement of the relevant professional organisations, a virtual electronic expert panel, the UK Multidrug-Resistant Tuberculosis Service, has been developed. This body gives advice via a secure website on MDR-TB patients referred by e-mail by clinicians across the country managing MDR-TB cases. In the first 2 years of operation, advice was sought on 60 patients with culture-proven MDR-TB (54% of the UK total). The number of clinicians accessing the advisory service increased from 27 in 2008 to 33 in 2009. Patients of non-UK origin accounted for 90% of all cases, including all four extensively drug-resistant tuberculosis cases. A central electronic virtual committee providing advice via a secure website has proved to be practical, economical and efficient. It could provide a model for MDR-TB management in other countries and for the management of other uncommon diseases.
引用
收藏
页码:950 / 954
页数:5
相关论文
共 16 条
  • [11] Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
    Kliiman, K.
    Altraja, A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (05) : 1085 - 1094
  • [12] Increasing antituberculosis drug resistance in the United Kingdom: analysis of national surveillance data
    Kruijshaar, Michelle E.
    Watson, John M.
    Drobniewski, Francis
    Anderson, Charlotte
    Brown, Timothy J.
    Magee, John G.
    Smith, E. Grace
    Story, Alistair
    Abubakar, Ibrahim
    [J]. BRITISH MEDICAL JOURNAL, 2008, 336 (7655): : 1231 - +
  • [13] Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1
  • [14] Levofloxacin treatment of active tuberculosis and the risk of adverse events
    Marra, F
    Marra, CA
    Moadebi, S
    Shi, P
    Elwood, RK
    Stark, G
    FitzGerald, JM
    [J]. CHEST, 2005, 128 (03) : 1406 - 1413
  • [15] Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC)
    Migliori, G. B.
    Sotgiu, G.
    Blasi, F.
    Zumla, A.
    Loddenkemper, R.
    Raviglione, M. C.
    Abubakar, I.
    Sandgren, A.
    Manissero, D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (03) : 493 - 495
  • [16] Fluoroquinolones for treating tuberculosis
    Ziganshina, L. E.
    Squire, S. B.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):